Is (BSTC) Outperforming Other Medical Stocks This Year?
Zacks.com featured highlights include: BioSpecificsTechnologies, eXp World, Elbit Systems and KoninklijkeVopak
Is (BSTC) Outperforming Other Medical Stocks This Year?
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in North America, today announced that its Board of Directors has adopted a stockholder rights plan to replace BioSpecifics' current rights plan, which has been terminated. BioSpecifics intends to submit the rights plan, which is similar to rights plans adopted by many other public companies, for stockholder ratification at its 2020 Annual Meeting of Stockholders.
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today announced that the Board of Directors has appointed Joseph Truitt as interim Chief Executive Officer. He will also serve on the Company's Board of Directors. Mr. Truitt succeeds J. Kevin Buchi, who served as CEO since October 2019, and has departed the company.
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today announced its financial results for the first quarter ended March 31, 2020.
Zacks.com featured highlights include: Gibraltar Industries, CBIZ, Integer, BioSpecifics Technologies and DHT
The latest analyst coverage could presage a bad day for BioSpecifics Technologies Corp. (NASDAQ:BSTC), with the...
Unfortunately for some shareholders, the BioSpecifics Technologies (NASDAQ:BSTC) share price has dived 32% in the last...
New Strong Buy Stocks for April 23rd
BioSpecifics (BSTC) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BioSpecifics Technologies (NASDAQ:BSTC) has had a great run on the share market with its stock up by a significant...
Let's take a look at the seven top-ranked stocks with impressive net profit margins for a winning portfolio.
Cash provides vitality and strength to a company. It holds the key to the company's existence, development and success, and can indeed be referred to as its lifeblood.
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today announced the appointment of Joseph Truitt as Chief Executive Officer. Mr. Truitt was appointed interim Chief Executive Officer by the Company's Board of Directors on April 6, 2020 and assumed this permanent role on May 7, 2020.
Zacks.com featured highlights include: PJT Partners, CBIZ, BioSpecifics Technologies, eXp World and Gibraltar Industries
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in North America, today announced that its Board of Directors appointed Mike Sherman and Corey Fishman to serve as Independent Directors, effective immediately. Mike Sherman and Corey Fishman will both join the Board's Audit Committee, with Mr. Sherman serving as an "audit committee financial expert." Corey Fishman will also join the Intellectual Property Committee.
New Strong Buy Stocks for April 15th
2 key valuation ratios suggest potential bargains Continue reading...